Post-traumatic stress disorder (PTSD) is a mental condition that can arise after traumatic experiences, affecting individuals' quality of life. Conventional treatment involves psychotherapy and pharmacotherapy, but does not always yield satisfactory results. In this context, MDMA-assisted psychotherapy has emerged as a promising alternative. This integrative review analyzed the efficacy and safety of MDMA as a therapeutic facilitator for PTSD. Nine clinical trials published between 2019 and 2024 were included. Results showed significant symptom reduction, greater therapeutic adherence, prolonged effects, and diagnostic remission in some patients.
A review of 17 controlled clinical trials examined psychedelics as an alternative treatment for major depressive disorder. Psilocybin, LSD, ketamine, and ayahuasca showed therapeutic potential, with patients experiencing clinical improvement in depression symptoms, reduced assessment scores, and improvement even in treatment-resistant cases. However, the authors note that current scientific evidence is insufficient to definitively support the therapeutic use of psychedelics for depression, and further research is needed.